Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Precision Medicine Has a Commercialization Problem
By: Chris PaquetteFounder and CEO, DeepIntent | As drug discovery is revolutionized by AI, the machinery built to get life-saving medicines to market remains trapped in a different era. Here’s how we solve that.
TL;DRAI
Over 50% of FDA approvals in 2023-2024 were for rare diseases; BioMarin withdrew Roctavian in 2026 due to commercial failure. Precision medicine requires AI-driven automation in patient engagement and stakeholder management to scale go-to-market.
1,448 words~7 min read
